Xinyi Geng1,2,3, Jianguo Zhang4, Yin Jiang4, Keyoumars Ashkan5, Thomas Foltynie6, Patricia Limousin6, Ludvic Zrinzo6, Alexander Green7, Tipu Aziz7, Peter Brown2, Shouyan Wang1. 1. Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, 88 Keling Road, SND, Suzhou 215163, China. 2. MRC Brain Network Dynamics Unit, University of Oxford, Mansfield Road, Oxford OX13TH, UK. 3. University of Chinese Academy of Sciences, 19A Yuquan Road, Shijingshan District, Beijing 100049, China. 4. Department of Neurosurgery, Beijing Tian-Tan Hospital, Beijing Neurosurgical Institute, Capital Medical University, 6 Tiantan West Road, Dongcheng District, Beijing 100050, China. 5. Institute of Psychiatry, Psychology and Neuroscience, Kings College London, Strand, London WC2R 2LS, UK. 6. Sobell Department of Motor Neuroscience & Movement Disorders, UCL Institute of Neurology, University College London, Gower Street, London WC1E 6BT, UK. 7. Nuffield Department of Clinical Neurosciences, University of Oxford, West Wing, John Radcliffe Hospital, Oxford OX39DU, UK.
Abstract
OBJECTIVES: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been successfully used to treat both Parkinson's disease (PD) and dystonia. Local field potentials (LFPs) recorded from the STN of PD patients demonstrate prominent beta frequency band activity. It is unclear whether such activity occurs in the STN in dystonia, and, if not, whether dystonia has another distinctive neural population activity in the STN. METHODS: Twelve patients with PD, and eight patients with dystonia underwent DBS electrode implantation targeting the STN. Seven dystonia patients were off medication and one was on aripiprazole and clonazepam. LFPs were recorded from the DBS electrodes in PD in the on/off medication states and in dystonia. Power spectra and temporal dynamics measured by the with Lempel-Ziv complexity of the LFPs were compared among these states. RESULTS: Normalised power spectra and Lempel-Ziv complexity of subthalamic LFPs differed between dystonia off and PD on/off, and between PD off and on over the low frequency, beta and high gamma bands. Patients with dystonia and off medication had lower beta power but higher low frequency and high gamma power than PD. Spectral power in the low beta frequency (11-20Hz) range was attenuated in medicated PD. CONCLUSION: The results suggest that dystonia and PD are characterized by different patterns of oscillatory activities even within the same nucleus, and exaggerated beta activity may relate to hypo-dopaminergic status.
OBJECTIVES: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) has been successfully used to treat both Parkinson's disease (PD) and dystonia. Local field potentials (LFPs) recorded from the STN of PD patients demonstrate prominent beta frequency band activity. It is unclear whether such activity occurs in the STN in dystonia, and, if not, whether dystonia has another distinctive neural population activity in the STN. METHODS: Twelve patients with PD, and eight patients with dystonia underwent DBS electrode implantation targeting the STN. Seven dystonia patients were off medication and one was on aripiprazole and clonazepam. LFPs were recorded from the DBS electrodes in PD in the on/off medication states and in dystonia. Power spectra and temporal dynamics measured by the with Lempel-Ziv complexity of the LFPs were compared among these states. RESULTS: Normalised power spectra and Lempel-Ziv complexity of subthalamic LFPs differed between dystonia off and PD on/off, and between PD off and on over the low frequency, beta and high gamma bands. Patients with dystonia and off medication had lower beta power but higher low frequency and high gamma power than PD. Spectral power in the low beta frequency (11-20Hz) range was attenuated in medicated PD. CONCLUSION: The results suggest that dystonia and PD are characterized by different patterns of oscillatory activities even within the same nucleus, and exaggerated beta activity may relate to hypo-dopaminergic status.
Authors: Andrea A Kühn; Noa Fogelson; Patricia Dowsey Limousin; Marwan I Hariz; Andreas Kupsch; Peter Brown Journal: Neuroreport Date: 2009-07-15 Impact factor: 1.837
Authors: Paul Silberstein; Antonio Oliviero; Vincenzo Di Lazzaro; Angelo Insola; Paolo Mazzone; Peter Brown Journal: Exp Neurol Date: 2005-08 Impact factor: 5.330
Authors: Andrea A Kühn; Florian Kempf; Christof Brücke; Louise Gaynor Doyle; Irene Martinez-Torres; Alek Pogosyan; Thomas Trottenberg; Andreas Kupsch; Gerd-Helge Schneider; Marwan I Hariz; Wim Vandenberghe; Bart Nuttin; Peter Brown Journal: J Neurosci Date: 2008-06-11 Impact factor: 6.167
Authors: Ewgenia Barow; Wolf-Julian Neumann; Christof Brücke; Julius Huebl; Andreas Horn; Peter Brown; Joachim K Krauss; Gerd-Helge Schneider; Andrea A Kühn Journal: Brain Date: 2014-09-10 Impact factor: 13.501
Authors: Bernadette C M van Wijk; Martijn Beudel; Ashwani Jha; Ashwini Oswal; Tom Foltynie; Marwan I Hariz; Patricia Limousin; Ludvic Zrinzo; Tipu Z Aziz; Alexander L Green; Peter Brown; Vladimir Litvak Journal: Clin Neurophysiol Date: 2016-02-01 Impact factor: 3.708
Authors: Robert S Eisinger; Jackson N Cagle; Enrico Opri; Jose Alcantara; Stephanie Cernera; Kelly D Foote; Michael S Okun; Aysegul Gunduz Journal: J Neurosci Date: 2020-02-27 Impact factor: 6.167
Authors: Doris D Wang; Coralie de Hemptinne; Svjetlana Miocinovic; Jill L Ostrem; Nicholas B Galifianakis; Marta San Luciano; Philip A Starr Journal: J Neurosci Date: 2018-04-16 Impact factor: 6.167
Authors: Andrea A Kühn; R Mark Richardson; Wolf-Julian Neumann; Robert S Turner; Benjamin Blankertz; Tom Mitchell Journal: Neurotherapeutics Date: 2019-01 Impact factor: 7.620
Authors: Huichun Luo; Yongzhi Huang; Xueying Du; Yunpeng Zhang; Alexander L Green; Tipu Z Aziz; Shouyan Wang Journal: Front Neurosci Date: 2018-04-11 Impact factor: 4.677